Last updated: February 24, 2026
What is the drug associated with NDC 52536-0510?
NDC 52536-0510 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), developed by Novartis. It is a gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients under 2 years of age. As of 2022, it remains the only approved gene therapy for SMA.
Market landscape overview
Treatment landscape
The SMA market comprises several therapies:
- Zolgensma (gene therapy): One-time infusion, high-cost.
- Spinraza (nusinersen): Intrathecal injections, repeated doses.
- Evrysdi (risdiplam): Oral administration, repeated doses.
Current sales and adoption
- For 2022, Zolgensma generated approximately $1.9 billion in global sales, representing rapid uptake driven by its single-dose regimen.
- The drug's market share in SMA treatments exceeds 50% among FDA-approved therapies for pediatric SMA, replacing older treatments like Spinraza in many cases.
Competitive positioning
- Zolgensma's one-time dosing provides an advantage over Spinraza and Evrysdi, which require ongoing administration.
- The therapy's cost is a critical factor, with the current list price generally quoted at $2.1 million per dose in the U.S., making it one of the most expensive drugs on the market.
Price and reimbursement considerations
List price
- Initial list price: Approximately $2.1 million per dose, as set by Novartis.
- Pricing strategies: Direct payment, outcomes-based agreements, and insurance negotiations influence the net price.
Reimbursement landscape
- The high cost has prompted payers to implement utilization controls and outcomes-based reimbursement models.
- Zolgensma received coverage decisions from CMS and private payers across the U.S., but access can vary based on formulary inclusion.
Price adjustments and discounts
- Novartis has reportedly offered discounts and rebates to payers to secure formulary position.
- Several markets outside the U.S. have negotiated lower prices, especially in Europe, where health technology assessment (HTA) evaluations influence pricing.
Market penetration and future growth
Drivers of growth
- Growing diagnosis rates due to improved screening.
- Age restrictions decreasing for treatment eligibility.
- Expansion into wider SMA patient populations, including older children.
Potential market size
- Estimated global SMA patient prevalence: 1 in 10,000 live births.
- Approximately 1,500 to 2,000 new pediatric SMA cases annually in the U.S.
- The total addressable market in developed countries projected to reach $3-4 billion by 2030, factoring in new indications and expanded age eligibility.
Challenges
- High cost limits access in some markets.
- Manufacturing capacity constraints could limit supply.
- Competition from emerging therapies and gene editing research.
Price projection analysis
Short-term outlook (2023-2025)
- The list price is unlikely to change significantly given current market dynamics.
- Discounting and rebates will continue to be used to improve market penetration.
- Immediate market expansion will be driven by increased coverage, especially in underserved regions, and expanding patient eligibility.
Long-term outlook (2025-2030)
- Price reductions of 10-20% could occur due to increased competition and pressure from payers.
- As manufacturing scales up and biosimilars or alternative gene therapies emerge, list prices may decline.
- The introduction of new formulations, such as lower-dose options, could also influence future pricing strategies.
Revenue forecasts
| Year |
Estimated Sales |
Key Factors |
| 2023 |
$2.2 billion |
Further payer coverage, increasing diagnosis rates |
| 2025 |
$2.8 billion |
Expanded indication, broader age coverage, competitive pressures |
| 2030 |
$3.5 billion |
Market saturation, new therapies, potential price adjustments |
Summary
- Market dominance: Zolgensma holds a significant share in pediatric SMA, with a high price point around $2.1 million per dose.
- Growth prospects: Increasing diagnosis rates and expanded guidelines support continued growth.
- Price trajectory: Expect steady pricing with potential discounts; long-term reductions may result from increased competition and manufacturing efficiencies.
Key Takeaways
- The SMA treatment market is competitive, with Zolgensma leading in pricing and innovation.
- Pricing strategies will adapt to payer negotiations, especially outside North America.
- Long-term growth depends on expanding patient access and addressing manufacturing constraints.
- Revenue projections suggest a potential increase to $3.5 billion globally by 2030.
- Price reductions may occur but are unlikely to significantly impact the current high-value positioning in the near term.
FAQs
Q1: Will the price of Zolgensma decrease significantly in the next five years?
A1: Likely minor reductions driven by market competition and manufacturing efficiencies; substantial price drops are not imminent unless new competitors enter the market.
Q2: How do reimbursement policies affect market penetration for Zolgensma?
A2: Different payers' coverage decisions and outcome-based payment models influence access, potentially limiting or expanding market reach.
Q3: Are there biosimilar or alternative gene therapies expected to challenge Zolgensma?
A3: Emerging gene therapies and gene editing approaches are under development, but none currently match Zolgensma's early market share or pricing.
Q4: What factors could influence global demand for Zolgensma?
A4: Diagnostic rates, approval of expanded indications, and reimbursement policies primarily drive demand.
Q5: How might future regulatory changes impact Zolgensma’s pricing and market access?
A5: Stricter HTA assessments, cost-effectiveness evaluations, or value-based pricing models could pressure prices and reimbursement terms.
References
- Novartis. (2022). Zolgensma (onasemnogene abeparvovec-xioi) prescribing information. Retrieved from https://www.novartis.com
- IQVIA. (2022). Pharma Sales Data.
- U.S. Food & Drug Administration. (2019). FDA approves Zolgensma for spinal muscular atrophy.
- Health Economics and Outcomes Research Digest. (2022). Gene Therapy Pricing and Reimbursement.
